OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
The OptimizeRx Board of Directors will make its formal recommendation regarding director nominations in the Company's definitive proxy statement which will be filed with the Securities and Exchange Commission and mailed to stockholders eligible to vote at the Company's 2025 Annual Meeting of Stockholders, which has not yet been scheduled.
About OptimizeRx
OptimizeRx is a leading healthcare technology company that's redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates', 'believes', 'estimates', 'expects', 'forecasts', 'intends', 'plans', 'projects', 'targets', 'designed', 'could', 'may', 'should', 'will' or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
Important Additional Information And Where To Find It
OptimIzeRx Corporation (the 'Company') plans to file proxy materials with the U.S. Securities and Exchange Commission (the 'SEC') in connection with the solicitation of proxies for the Company's 2025 annual meeting of stockholders (the '2025 Annual Meeting'). Prior to the 2025 Annual Meeting, the Company will file a definitive proxy statement (the 'Proxy Statement') together with a WHITE proxy card. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able to obtain, free of charge, copies of the Proxy Statement, any amendments or supplements thereto and any other documents (including the WHITE proxy card) when filed by the Company with the SEC at the SEC's website ( http://www.sec.gov) or at the Company's website at https://www.optimizerx.com/ or by contacting Andy D'Silva, SVP - Finance, by email at [email protected] or by mail at OptimizeRx Corporation, 260 Charles Street, Suite 302, Waltham, MA 02453.
Certain Information Regarding Participants
The Company, its directors, certain of its executive officers, and other employees may be deemed to be 'participants' (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from stockholders in connection with the 2025 Annual Meeting. Additional information regarding the identity of these participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Annual Meeting. Information relating to the foregoing can also be found in the Company's definitive proxy statement for its 2024 annual meeting of stockholders, filed with the SEC on April 29, 2024. To the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2024 proxy statement, such changes have been reflected in the following Statements of Change in Beneficial Ownership on Form 4 filed with the SEC with respect to the Company: Form 4, filed by Stephen L. Silvestro on March 4, 2025; Form 4, filed by Stephen L. Silvestro on February 20, 2025; Form 4, filed by Edward Stelmakh on February 20, 2025; Form 4, filed by Cathy Klema on February 4, 2025; Form 4/A, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Stephen L. Silvestro on December 27, 2024; Form 4, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Edward Stelmakh on December 20, 2024; Form 4, filed by Stephen L. Silvestro on December 20, 2024; Form 4, filed by Edward Stelmakh on October 15, 2024; Form 4, filed by Stephen L. Silvestro on October 7, 2024; Form 4, filed by Edward Stelmakh on October 7, 2024; Form 4, filed by Gregory D. Wasson on June 11, 2024; Form 4, filed by Cathy Klema on June 11, 2024; Form 4, filed by Ellen O'Connor Vos on June 11, 2024; Form 4, filed by James Paul Lang on June 11, 2024; Form 4, filed by Patrick Spangler on June 11, 2024; Form 4/A, filed by Stephen L. Silvestro on May 6, 2024; Form 4, filed by Stephen L. Silvestro on May 6, 2024; and Form 4/A, filed by Stephen L. Silvestro on May 6, 2024. These filings can be found at the SEC's website at www.sec.gov. More detailed and updated information regarding the identity of participants in the solicitation, and their direct or indirect interests (by security holdings or otherwise), will be set forth in the Proxy Statement and other materials to be filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
OptimizeRx Contact
Investor Relations Contact
Sandya von der Weid
LifeSci Advisors, LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why SoundHound AI's (SOUN) Amelia Acquisition Could Pay Off in the Long Run
SoundHound AI, Inc. (NASDAQ:SOUN) is one of the AI Stocks Analysts Are Watching Closely. On August 11, Ladenburg Thalmann analyst Glenn Mattson upgraded the stock from Neutral to Buy with a price target of $16.00 (from $9.00). The rating upgrade comes after Soundhound posted second-quarter revenue well above expectations driven by its large contract wins. According to the firm, momentum in core verticals is helping offset previous concerns about low-margin contracts from the Amelia acquisition. These are anticipated to be phased out over the next 18 months. The firm also believes that SoundHound is building a broader platform that may link automotive, restaurant and enterprise customers into a voice-enabled ecosystem. This will in turn create lead-generation revenue streams. A Wall Street analyst reviewing stock information on a computer, examining data points for a new investment opportunity. 'We upgrade shares to Buy and raise our PT to $16 (from $9). We continue to view Voice as one of the key early applications for AI systems. The company is a leader in this space and is adding significant utility for enterprises looking to adopt AI functionality. The Amelia acquisition still needs further integration but is providing solid benefits in terms of scale, new lead generation, and an entry into the enterprise. While valuation remains elevated, the growth and scale justify that premium, in our view. We now use a 22x multiple on our new 2027 estimate to achieve our $16 PT. This is justified by the rule of 40 peer set found in the body of the report.' SoundHound AI, Inc. (NASDAQ:SOUN) is a voice artificial intelligence company offering voice AI solutions to businesses. While we acknowledge the potential of SOUN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
CORRECTED RELEASE: Amaze Reports Second Quarter 2025 Financial Results with 1,134% Year-Over-Year Revenue Growth
Amaze Holdings, Inc. (the 'Company') is replacing in its entirety its earnings press release for the second quarter ended June 30, 2025, originally issued on August 14, 2025, to correct certain disclosures contained in the tables entitled 'Condensed Consolidated Balance Sheets' for the period ended June 30, 2025, the 'Condensed Consolidated Statement of Operations' for the three and six months ended June 30, 2025, and the 'Condensed Consolidated Statements of Cash Flows' for the six months ended June 30, 2025 as well as the corresponding figures included in the narrative sections in the earnings release for net loss and net loss per share for the three months ended June 30, 2025. Other than the corrections discussed herein, all other information disclosed in the earnings release remains unchanged. The updated earnings release reads: Amaze Reports Second Quarter 2025 Financial Results with 1,134% Year-Over-Year Revenue Growth Accompanying Shareholder Letter Available at With Q2 Revenue Baseline, Company Expects Sequential Topline Growth for Remainder of 2025 NEWPORT BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Amaze Holdings, Inc. (NYSE American: AMZE) ('Amaze' or the 'Company'), a global leader in creator-powered commerce, today reported financial results for the second quarter ended June 30, 2025. Recent Operational Highlights Surpassed 200 million lifetime storefront visits and 12 million active creators, underscoring the Amaze platform's scale and influence in the rapidly expanding creator economy. Announced several marquee partnerships in recent weeks, including Alex Caruso, Jamvana, Loaded Dice, Nutrius, and Ghost Gaming, among others. Partnered with Picsart, allowing users to turn their digital art, edits, and designs into physical products such as hoodies, stickers, and tote bags to sell. Began beta testing program for Amaze Digital Fits, a web-based tool will enable Roblox creators to design avatar fashion with no 3D experience required. Partnered with VisitIQ allowing Amaze to analyze, visualize, and activate first-party fan and creator data across its fast-growing platform, enabling Amaze to turn deep audience insights into smarter marketing, more comprehensive creator support, and product innovation. Launched digital payment strategy designed to modernize global payments, unlock new monetization tools, and enhance financial flexibility, emphasizing Amaze's assertive push to lead in payment innovation. Formed strategic partnership with Parler, enabling creators to sell products directly through Parler's growing network of social media properties including PlayTV and Management Commentary'In our first full quarter as a public company, we took important steps to position Amaze for long-term success,' said Aaron Day, CEO of Amaze. 'To solidify our position as the go-to platform for creators, we launched new integrations like Express Checkout and AI-driven selling tools, and we also expanded monetization opportunities to Roblox players and Picsart users. These innovations helped us surpass 200 million storefront visits and over 12 million active creators on the platform. 'Financially, we generated $0.87 million in net revenue this quarter, which we view as a strong baseline for future growth. Over the past several quarters, we've devoted significant time and effort to recapitalize the business and retool our technology infrastructure. With both initiatives far along, we now have improved liquidity to strategically invest in our business, which we expect to lead to accelerating topline growth and improved KPI performance through the second half of the year.' Key Performance Indicators (KPIs) Gross Merchandise Value (GMV): $3.77 million Average Order Value (AOV): $50.00 (1H 2025) U.S. Conversion Rate: .41% of all traffic Creator Lifetime Value (LTV): $200.00 Total Active Creators with Stores: Over 12 million Total Number of Active Visitors: Over 200 million Second Quarter 2025 Financial ResultsResults compare the second quarter ended June 30, 2025 ('Q2 2025') to the second quarter ended June 30, 2024 ('Q2 2024') unless otherwise indicated. Results from Q2 2024 represent only Fresh Vine Wine, Inc. results. Total revenue increased 1,134% to $0.87 million in Q2 2025 from $0.07 million in the same year-ago period. The increase in net contribution revenue was mostly attributable to the addition of sales from Amaze as the Company closed the acquisition during the first quarter of 2025. Gross profit increased 1,903% to $0.79 million in Q2 2025 from $(0.04) million in the same year-ago period. The increase in gross profit is primarily due to the operating leverage of the Amaze platform, which enables high-margin digital and physical sales with lower incremental cost compared to traditional wholesale models. Net loss was $5.0 million, or $(3.14) per share, in Q2 2025 compared to net loss of $0.88 million, or $(1.30) per share, in the same year-ago period. The increase in net loss is largely driven by a $4.0 million increase in SG&A expenses that are primarily related to operating costs associated with Amaze's creator-focused business model, including personnel, legal and professional services related to the reverse merger, and marketing costs to support platform growth. The Company had $0.31 million in cash at June 30, 2025, compared to $0.16 million at December 31, 2024. OutlookAmaze management expects to build on the base provided by its Q2 performance, both at the top and bottom line. The Company foresees net revenue continuing to ramp sequentially in Q3 as well as into Q4. As a result of these material topline increases, combined with additional organizational efficiencies, Amaze also expects to generate a temporary profit in Q4 2025/Q1 2026 due to an increase in sales related to the seasonality of the business. Amaze's Q3 2025, Q4 2025 and Q1 2026 financial outlook is based on a number of assumptions that are subject to change and many of which are outside our control. If actual results vary from these assumptions, our expectations may change. There can be no assurance that we will achieve these results. Shareholder LetterAmaze management also posted a letter to shareholders on its Investor Relations website ( which further details the company's results, discusses various business initiatives, and provides a future financial and industry outlook. For investor information, please contact IR@ press inquiries, please contact PR@ Available InformationWe periodically provide other information for investors on our corporate website, and our investor relations website, This includes press releases and other information about financial performance, information on corporate governance, and details related to our annual meeting of stockholders. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor our website, in addition to following the Company's press releases, SEC filings, and public conference calls and webcasts. About AmazeAmaze Holdings, Inc. is an end-to-end, creator-powered commerce platform offering tools for seamless product creation, advanced e-commerce solutions, and scalable managed services. By empowering anyone to 'sell anything, anywhere,' Amaze enables creators to tell their stories, cultivate deeper audience connections, and generate sustainable income through shoppable, authentic experiences. Discover more at Cautionary Note Regarding Forward-Looking StatementsThis press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements relate to future events and developments or to our future operating or financial performance, are subject to risks and uncertainties and are based estimates and assumptions. Forward-looking statements may include, but are not limited to, statements about our Q3 2025 and Q4 2025/Q1 2026 financial outlook, strategies, initiatives, growth, revenues, expenditures, the size of our market, our plans and objectives for future operations, and future financial and business performance. These statements can be identified by words such as such as 'may,' 'might,' 'should,' 'would,' 'could,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'outlook,' 'estimate,' 'predict,' 'potential' or 'continue,' and are based our current expectations and views concerning future events and developments and their potential effects on us. These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statement. These risks include: our ability to execute our plans and strategies; our limited operating history and history of losses; our financial position and need for additional capital; our ability to attract and retain our creator base and expand the range of products available for sale; we may experience difficulties in managing our growth and expenses; we may not keep pace with technological advances; there may be undetected errors or defects in our software or issues related to data computing, processing or storage; our reliance on third parties to provide key services for our business, including cloud hosting, marketing platforms, payment providers and network providers; failure to maintain or enhance our brand; our ability to protect our intellectual property; significant interruptions, delays or outages in services from our platform; significant data breach or disruption of the information technology systems or networks and cyberattacks; risks associated with international operations; general economic and competitive factors affecting our business generally; changes in laws and regulations, including those related to privacy, online liability, consumer protection, and financial services; our dependence on senior management and other key personnel; and our ability to attract, retain and motivate qualified personnel and senior management. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other future filings and reports that we file with the Securities and Exchange Commission (SEC) from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the press release. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. -Financial Tables to Follow- AMAZE HOLDINGS, CONSOLIDATED BALANCE SHEETS(Unaudited) June 30,2025 December 31,2024 (unaudited) Assets Current assets Cash $ 239,604 $ 155,647 Restricted cash 71,079 — Accounts receivable, net of allowance for credit losses of $9,476 and $13,400 as of June 30, 2025 and December 31, 2024, respectively 2,381 6,966 Note receivable — 3,500,000 Equity investment — 466,500 Inventories 184,540 212,494 Prepaid expenses and other 815,252 33,830 Interest receivable — 36,888 Total current assets 1,312,856 4,412,325 Fixed assets, net Computer equipment, net 7,022 — Goodwill 97,609,814 — Total assets $ 98,929,692 $ 4,412,325 Liabilities and stockholders' equity Current liabilities Accounts payable $ 9,586,411 $ 1,108,777 Accrued compensation 337,690 — Accrued creator commissions 2,441,450 — Settlement payable 622,839 484,735 Accrued expenses 2,502,979 596,610 Accrued expenses - related parties 309,333 309,333 Accrued sales tax 1,959,219 — Deferred revenue 4,140,533 1,919 Financing arrangement, net of discount 517,021 — Convertible notes payable, net of discount 392,142 432,105 Notes payable, current portion, net of discount 5,493,325 — Total current liabilities 28,302,942 2,933,479 Total liabilities 28,302,942 2,933,479 Commitment and contingencies - Note 16 Stockholders' equity Series A preferred stock, $0.001 par value – 10,000 shares authorized at June 30, 2025 and December 31, 2024; 7,013 shares issued and outstanding at June 30, 2025 and December 31, 2024, preference in liquidation of $1,344,723 and $1,597,706 at June 30, 2025 and December 31, 2024, respectively 7 9 Series B preferred stock, $0.001 par value – 50,000 shares authorized at June 30, 2025 and December 31, 2024; 39,250 shares issued and outstanding at June 30, 2025 and December 31, 2024, preference in liquidation of $5,887,500 at June 30, 2025 and December 31, 2024 39 50 Series C preferred stock, $0.001 par value – 100,000 and 0 shares authorized at June 30, 2025 and December 31, 2024, respectively; 8,550 and 0 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively; preference in liquidation of $855,000 and $0 at June 30, 2025 and December 31, 2024, respectively 9 — Series D preferred stock, $0.001 par value – 750,000 and 0 shares authorized at June 30, 2025 and December 31, 2024, respectively; 0 and 0 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively; preference in liquidation of $0 and $0 at June 30, 2025 and December 31, 2024, respectively — — Common stock, $0.001 par value - 100,000,000 shares authorized at June 30, 2025 and December 31, 2024; 5,108,649 shares issued and outstanding at June 30, 2025 and December 31, 2024 5,110 776 Additional Paid-In Capital 107,027,294 30,636,812 Accumulated deficit (36,405,709 ) (29,158,801 ) Total stockholder's equity 70,626,750 1,478,846 Total liabilities and stockholders' equity $ 98,929,692 $ 4,412,325 AMAZE HOLDINGS, CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) For the Three Months Ended For the Six Months Ended June 30,2025 June 30,2024 June 30,2025 June 30,2024 Revenues $ 869,884 $ 70,484 $ 930,098 $ 175,052 Cost of revenues 82,372 114,160 145,162 329,976 Gross income (Loss) 787,512 (43,676 ) 784,936 (154,924 ) Selling, general and administrative expenses 4,881,391 834,267 6,768,134 1,933,748 Equity-based compensation 190,359 1,626 190,359 3,251 Depreciation 1,674 — 2,232 — Operating loss (4,285,912 ) (879,569 ) (6,175,789 ) (2,091,923 ) Other income (expense) Other income (expense) (27,379 ) — (139 ) 39 Interest expense (684,116 ) — (924,988 ) — Realized loss on equity investment (50,760 ) — (54,760 ) — Gain on extinguishment of liabilities — — 18,301 — Total other income (expense) (762,255 ) — (961,586 ) 39 Net loss (5,048,167 ) (879,569 ) (7,137,375 ) (2,091,884 ) Series A preferred dividends 53,433 26,133 109,533 56,133 Net loss attributable to common stockholders $ (5,101,600 ) $ (905,702 ) $ (7,246,908 ) $ (2,148,017 ) Weighted average shares outstanding Basic 1,622,169 694,619 1,174,419 694,619 Diluted 1,622,169 694,619 1,174,419 694,619 Net loss per share - basic $ (3.14 ) $ (1.30 ) $ (6.17 ) $ (3.09 ) Net loss per share - diluted $ (3.14 ) $ (1.30 ) $ (6.17 ) $ (3.09 ) AMAZE HOLDINGS, CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) Six Months EndedJune 30, 2025 2024 Cash flows from operating activities Net loss $ (7,137,375 ) $ (2,091,884 ) Adjustments to reconcile net loss to net cash used in operating activities: Amortization of original issue discount 699,354 — Depreciation expense 2,232 — Realized loss on equity investment (54,760 ) — Gain on extinguishment of liabilities (18,301 ) — Equity-based compensation 190,359 3,251 Inventory write-downs — 154,483 Changes in operating assets and liabilities: Accounts receivable 28,801 134,588 Inventories 27,954 81,939 Prepaid expenses and other (270,985 ) 20,026 Interest receivable (41,293 ) — Accounts payable 2,115,073 603,489 Accrued compensation 337,690 — Settlement payable 156,405 — Accrued creator commissions 25,195 — Accrued expenses (300,312 ) 147,685 Accrued sales tax (32,382 ) — Deferred revenue 370,064 (139 ) Net cash used in operating activities (3,902,281 ) (946,562 ) Cash flows from investing activities Cash acquired through acquisition (Note 2) 591,686 — Issuance of note receivable (900,000 ) — Net cash used in investing activities (308,314 ) — CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from notes payable net of issuance costs 2,488,241 15,000 Proceeds from financing arrangement net of issuance cost 714,754 — Proceeds from convertible notes payable 264,881 — Proceeds from issuance of Series B preferred stock - net of issuance costs — 805,017 Proceeds from issuance of Series C preferred stock - net of issuance costs 785,067 — Repayment of financing arrangement (363,365 ) — Warrants issued in conjunction with debt 213,553 — Payments on note payable — (15,000 ) Issuance of common stock in conjunction with securities purchase agreement 262,500 — Net cash provided by financing activities 4,365,631 805,017 Net change in cash and restricted cash 155,036 (141,545 ) Cash and restricted cash at beginning of period 155,647 336,340 Cash and restricted cash at end of period $ 310,683 $ 194,795 Supplemental disclosure of cash flow information: Acquisition through issuance of Series D and Merger Warrants $ 75,000,000 $ — Repayment of debt with investment 521,260 — Forgiveness of note receivable and interest with note payable and interest from Acquisition 4,478,181 — Warrants issued in conjunction with debt 213,553 — Issuance cost in conjunction with name change 56,667 — Accrued Series A dividends $ 109,533 $ 56,133 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
